Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The claim about Synjardy 12.5/1000 mg consisting of empagliflozin 12.5 mg plus metformin 1000 mg in one tablet is consistent with the label’s stated active ingredients (empagliflozin + metformin HCl). No direct contraindications, warnings, dosage instructions, or population-specific restrictions are asserted by the claim.
Category Scores
Accurate Statements
Synjardy 12.5/1000 mg suele referirse a una combinación de empagliflozina 12.5 mg y metformina 1000 mg en una sola tableta.
Supported in part by label excerpt that SYNJARDY is a combination of empagliflozin and metformin HCl (Drug label active ingredients). The provided excerpts do not explicitly list the 12.5 mg and 1000 mg strengths, but the active ingredient combination matches.
Unsupported Statements
12.5/1000 mg corresponds specifically to empagliflozin 12.5 mg + metformin 1000 mg.
The supplied label excerpts confirm the combination is empagliflozin + metformin HCl but do not explicitly state the numeric strength mapping (12.5 mg and 1000 mg) for the 12.5/1000 mg product.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claim is about strength/combination composition only and does not assert dosing instructions, contraindications, or management of safety risks.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Numeric strength mapping (12.5 mg and 1000 mg) is not explicitly supported by the provided label excerpts.
Suggested Improvement
Limit the statement to what is explicitly supported (that Synjardy is empagliflozin + metformin HCl) unless the label excerpt includes the specific 12.5/1000 mg strength-to-dose correspondence.